Award details

Developing the Nanokick Bioreactor for Commercialisation and Cell Therapy

Reference	BB/S018808/1
Principal Investigator / Supervisor	Professor Matthew Dalby
Co-Investigators / Co-Supervisors	Professor Stuart Reid, Professor Manuel Salmeron-Sanchez
Institution	University of Glasgow
Department	College of Medical, Veterinary, Life Sci
Funding type	Research
Value (£)	582,280
Status	Completed
Type	Research Grant
Start date	02/09/2019
End date	01/04/2022
Duration	31 months

Abstract

unavailable

Summary

There is a >£1B market emerging for engineered bone graft, including products containing mesenchymal stem cells (MSCs). However, MSCs don't produce bone, osteoblasts do. Previous BBSRC funding has helped develop our Nanokick bioreactor for chemical-free supply of osteogenic, bone forming, cells. Here, we will address technical, regulatory and commercial objectives towards manufacture of a genuinely scalable allogeneic cell therapy for bone grafting. We have already secured funding for a first-in-man study in 2021. However, this project will address the regulatory and process specific technological challenges to supplying clinical grade cells for large trials and, ultimately, as a marketed therapeutic product. This same challenge of scalable manufacture has slowed or ceased progress of many cellular therapies, therefore the processes being developed here are expected to have wider impact in the cell therapy sector.

Committee	Not funded via Committee
Research Topics	Industrial Biotechnology, Regenerative Biology, Stem Cells
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search